Phase 3 HERIZON-GEA-01 Results Published In The New England Journal Of Medicine Show Durable And Consistent Survival Benefit With Ziihera® (Zanidatamab-Hrii) Combinations In First-Line HER2+ Locally Advanced Or Metastatic GEA

(MENAFN - PR Newswire) Expanded safety, subgroup, progression-free survival sensitivity and subsequent therapy analyses further characterize the consistency and durability of outcomes observed with ...